Biomea Fusion announced that it is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes; At Week 26, 22 weeks after the last dose of BMF-219, participants in the 100 mg QD (without food) cohort saw an improved placebo adjusted mean reduction in HbA1c of 0.8% (compared to a 0.7% placebo adjusted mean reduction in HssA1c at Week 4); Observed HbA1C reduction was supported by an increase from baseline in placebo adjusted mean HOMA-B (+270%) and in mean stimulated C-peptide AUC (+22%) at Week 26 in responders (defined as HbA1c reduction 0.5% at Week 26) with baseline below the HOMA-B upper limit of normal (2, and had poorly controlled diabetes (HbA1c 7.0% and 10%). At baseline, diabetic patients in Cohorts 2 and 3 had a mean HbA1c of 8.0% and 8.1%, respectively.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.52 USD | +0.57% | -4.36% | -27.55% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.55% | 378M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- BMEA Stock
- News Biomea Fusion, Inc.
- Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes